SCHEMBL24740258

SCHEMBL24740258

CC(C)NC(=O)OCC(C)(C)c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46
HPGD P15428 3/20 0.43
ALDH1A1 P00352 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSH P09668 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
ALOX15 P16050 1/20 0.41
RAB9A P51151 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28951840 0.86 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL28951838 0.86 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30428422 0.86 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30174718 0.86 NOS3 (0.46) MAPTCTSLCTSBCTSHCTSS
SCHEMBL25527526 0.86 NOS3 (0.46) MAPTCTSLCTSBCTSHCTSS
SCHEMBL28951508 0.86 NOS3 (0.46) MAPTCTSLCTSBCTSHCTSS
SCHEMBL25758756 0.85 CTSL (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25221056 0.85 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL25200049 0.85 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30174654 0.85 MAPT (0.42) MAPTGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL MAPT 1905/4885GRIN2D 4204/4885GRIN3B 3426/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV MAPT 2314/4885GRIN2D 3878/4885GRIN3B 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.